Hereditary Transthyretin Amyloidosis (hATTR) Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Alnylam, Akcea, Ionis, AstraZeneca, Eidos, Corino, Prothena

Hereditary Transthyretin Amyloidosis (hATTR) Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Alnylam, Akcea, Ionis, AstraZeneca, Eidos, Corino, Prothena
Delveinsight Business Research LLP
As per DelveInsight, the Hereditary Transthyretin Amyloidosis (hATTR) Market market size in the seven major markets was found to be USD 973.5 million in 2020, which is expected to grow by 2032. The United States accounts for the largest market size of hATTR compared to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. In the United States, the market size of hATTR was found to be USD 529.6 million in 2020.

The hATTR market is expected to grow owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

DelveInsight’s “Hereditary Transthyretin Amyloidosis (hATTR) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Transthyretin Amyloidosis (hATTR) Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Hereditary Transthyretin Amyloidosis (hATTR) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hereditary Transthyretin Amyloidosis (hATTR) Market

Hereditary Transthyretin Amyloidosis (hATTR): An Overview

Hereditary transthyretin amyloidosis (hATTR), an inherited, rapidly progressive, and life-threatening disease, is caused by a mutation in the transthyretin (TTR) gene that results in misfolded TTR proteins accumulating as amyloid fibrils in multiple sites, including the nerves, heart, and gastrointestinal tract. TTR protein is produced primarily in the liver and is usually a carrier for retinol-binding protein—one of the media used to transport vitamin A around the body.

hATTR amyloidosis involves many systems in the body and can result in a wide variety of symptoms, including sensory and motor, autonomic (e.g., diarrhea, hypotension, erectile dysfunction), and cardiac symptoms.

Hereditary Transthyretin Amyloidosis (hATTR) Market Key Facts

  • The total diagnosed prevalent cases of hATTR in the 7MM were estimated to be 13,540 in 2020.

  • Epidemiology assessed for the condition showed that the US, in 2020, accounted for approximately 15,312 prevalent cases of hATTR.

  • Among the EU-5 countries in 2020, France had the highest diagnosed prevalent cases of hATTR, with 1,480 cases. In contrast, Germany had the lowest cases (518) in 2020.

  • Current market dynamics comprise approved therapies like Tafamidis, Inotersen, Patisiran (Onpattro), and other off-label therapies.

  • Potential Therapies expected to launch are as follows Vutrisiran (Alnylam Pharmaceuticals), Eplontersen (AKCEA-TTR-LRx) (Ionis Pharmaceuticals), Acoramidis (Eidos Therapeutics), CRX-1008 (Tolcapone) (Corino Therapeutics), PRX004 (Prothena/Novo Nordisk), and others. The launch of these therapies may increase market size in the coming years, assisted by an increase in the hATTR patient pool.

Hereditary Transthyretin Amyloidosis (hATTR) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Hereditary Transthyretin Amyloidosis (hATTR) market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Segmentation

  • Diagnosed Prevalent Population of hATTR

  • Type-specific Diagnosed Prevalent Cases of hATTR

  • Stage-Specific Diagnosed Prevalent Population of FAP 

  • Treatable Diagnosed Prevalent Population of hATTR

Hereditary Transthyretin Amyloidosis (hATTR) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis (hATTR) market or expected to get launched during the study period. The analysis covers Hereditary Transthyretin Amyloidosis (hATTR) market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hereditary Transthyretin Amyloidosis (hATTR) Market Will Evolve by 2032 @

Some of the key companies in the Hereditary Transthyretin Amyloidosis (hATTR) Therapeutic Market include:

  • Pfizer

  • Alnylam Pharmaceuticals

  • Akcea Therapeutics

  • Ionis Pharmaceuticals

  • AstraZeneca

  • Eidos Therapeutics

  • Corino Therapeutics

  • Prothena

  • Novo Nordisk

  • Intellia Therapeutics

  • Regeneron Pharmaceuticals

And many others

Hereditary Transthyretin Amyloidosis (hATTR) Therapies analyzed and covered in the report include:

  • Vyndaqel: Pfizer

  • Onpattro: Alnylam Pharmaceuticals

  • Tegsedi: Akcea Therapeutics/Ionis Pharmaceuticals

  • Vutrisiran: Alnylam Pharmaceuticals

  • Eplontersen: Ionis Pharmaceuticals/ AstraZeneca 

  • Acoramidis (AG 10): Eidos Therapeutics

  • CRX-1008 (Tolcapone; SOM0226): Corino Therapeutics

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hereditary Transthyretin Amyloidosis (hATTR) Competitive Intelligence Analysis

4. Hereditary Transthyretin Amyloidosis (hATTR) Market Overview at a Glance

5. Hereditary Transthyretin Amyloidosis (hATTR) Disease Background and Overview

6. Hereditary Transthyretin Amyloidosis (hATTR) Patient Journey

7. Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology and Patient Population (In US, EU5, and Japan)

8. Hereditary Transthyretin Amyloidosis (hATTR) Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Transthyretin Amyloidosis (hATTR) Unmet Needs

10. Key Endpoints of Hereditary Transthyretin Amyloidosis (hATTR) Treatment

11. Hereditary Transthyretin Amyloidosis (hATTR) Marketed Products

12. Hereditary Transthyretin Amyloidosis (hATTR) Emerging Drugs and Latest Therapeutic Advances

13. Hereditary Transthyretin Amyloidosis (hATTR) Seven Major Market Analysis

14. Attribute Analysis

15. Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook (In US, EU5, and Japan)

16. Hereditary Transthyretin Amyloidosis (hATTR) Access and Reimbursement Overview

17. KOL Views on the Hereditary Transthyretin Amyloidosis (hATTR) Market

18. Hereditary Transthyretin Amyloidosis (hATTR) Market Drivers

19. Hereditary Transthyretin Amyloidosis (hATTR) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Barlow’s Syndrome Market

“Barlow’s Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Barlow’s Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States